Rhythm Pharmaceuticals, Inc.
RYTM
$90.51
$3.133.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.87% | 54.28% | 66.80% | 25.94% | 72.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.87% | 54.28% | 66.80% | 25.94% | 72.61% |
| Cost of Revenue | 26.80% | 43.65% | 88.09% | 29.96% | 17.14% |
| Gross Profit | 37.87% | 55.66% | 64.40% | 25.46% | 81.15% |
| SG&A Expenses | 50.75% | 48.19% | 26.18% | 13.68% | 17.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,219.87% | 34.76% | 34.85% | 8.51% | -114.22% |
| Operating Income | -192.02% | -19.98% | -11.90% | 1.02% | 223.94% |
| Income Before Tax | -9.58% | -20.03% | -45.66% | 64.97% | -4.69% |
| Income Tax Expenses | 65.56% | 132.27% | -29.65% | -73.33% | -145.92% |
| Earnings from Continuing Operations | -9.73% | -21.23% | -44.55% | 64.99% | -3.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.73% | -21.23% | -44.55% | 64.99% | -3.98% |
| EBIT | -192.02% | -19.98% | -11.90% | 1.02% | 223.94% |
| EBITDA | -190.81% | -20.34% | -12.05% | 0.98% | 226.15% |
| EPS Basic | -0.79% | -11.52% | -36.96% | 65.72% | -3.06% |
| Normalized Basic EPS | -189.30% | -10.91% | -9.02% | 3.16% | 213.72% |
| EPS Diluted | -0.79% | -11.52% | -36.96% | 65.72% | -3.06% |
| Normalized Diluted EPS | -189.30% | -10.91% | -9.02% | 3.16% | 213.72% |
| Average Basic Shares Outstanding | 8.57% | 8.23% | 4.38% | 4.85% | 4.03% |
| Average Diluted Shares Outstanding | 8.57% | 8.23% | 4.38% | 4.85% | 4.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |